Search / Trial NCT06236152

Steroids vs Placebo in Treatment of Tuberculous Lymphadenitis

Launched by FAHAD JAVED AWAN · Jan 23, 2024

Trial Information

Current as of December 22, 2024

Completed

Keywords

Painful Cervical Lymphadenopathy Tuberculosis Tuberculous Lymphadenitis

ClinConnect Summary

Tuberculosis earliest records date back to the origin of civilization itself and yet still it remains one of the most elusive of the diseases still haunting the human population in the third world. Newer dugs and treatment protocols are still remain a major focus of discussion in the academic circles. Pakistan accounts for around 60% of the cases of tuberculosis in the East Mediterranean with an overall prevalence reaching 376 cases per 100,000 population. With such a high prevalence of the disease, it becomes punitive that robust TB control programs are run with an aim of not only rooting ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Newly diagnosed patients with tuberculosis having painful tuberculous lymphadenopathy
  • Exclusion Criteria:
  • 1. Patients with no tuberculous lymphadenopathy.
  • 2. Patients who are already under treatment for tuberculosis.
  • 3. Patient who developed complications due to anti-TB treatment

Trial Officials

Fahad J Awan, MBBS

Principal Investigator

Pak Emirates Military Hospital

Muhammad Uneeb Ullah, MBBS

Principal Investigator

Pak Emirates Military Hospital

About Fahad Javed Awan

Fahad Javed Awan is a dedicated clinical trial sponsor focused on advancing medical research through innovative and rigorous study designs. With a commitment to enhancing patient care and outcomes, Mr. Awan leverages extensive expertise in clinical development, regulatory compliance, and operational management. His leadership fosters collaborative partnerships with healthcare professionals and research institutions, ensuring the successful execution of trials across various therapeutic areas. By prioritizing ethical standards and patient safety, Fahad Javed Awan aims to contribute significantly to the advancement of medical knowledge and the development of new therapies.

Locations

Rawalpindi, Punjab, Pakistan

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0